References
- Medlock J, Pandey A, Parpia ASet al.Effectiveness of UNAIDS targets and HIV vaccination across 127 countries. Proc Natl Acad Sci USA 2017;114: 4017–4022.
- Fauci AS, Marston HD.Focusing to achieve a world without AIDS. JAMA 2015;313: 357–358.
- Kim JH, Excler JL, Michael NL.Lessons from the RV144 Thai phase III HIV-1 vaccine trial and the search for correlates of protection. Annu Rev Med 2015;66: 423–437.
- Lelievre JD, Levy Y.HIV-1 prophylactic vaccines: state of the art. J Virus Erad 2016;2: 5–11.
- Rerks-Ngarm S, Pitisuttithum P, Nitayaphan Set al.Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009;361: 2209–2220.
- Haynes BF, Gilbert PB, McElrath MJet al.Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 2012;366: 1275–1286.
- Bruel T, Guivel-Benhassine F, Lorin Vet al.Lack of ADCC breadth of human nonneutralizing anti-HIV-1 antibodies. J Virol 2017;91: pii: e02440-16.
- Pinter A, Honnen WJ, Kayman SCet al.Potent neutralization of primary HIV-1 isolates by antibodies directed against epitopes present in the V1/V2 domain of HIV-1 gp120. Vaccine 1998;16: 1803–1811.
- Sun Z, Zhu Y, Wang Qet al.An immunogen containing four tandem 10E8 epitope repeats with exposed key residues induces antibodies that neutralize HIV-1 and activates an ADCC reporter gene. Emerg Microbes Infect 2016;5: e65.
- Walker LM, Phogat SK, Chan-Hui PYet al.Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009;326: 285–289.
- Bruel T, Guivel-Benhassine F, Amraoui Set al.Elimination of HIV-1-infected cells by broadly neutralizing antibodies. Nat Commun 2016;7: 10844.